Hereditary angioedema: lanadelumab cuts attack rates

Subcutaneous lanadelumab for 26 weeks reduced the rate of attacks in patients with hereditary angioedema type I or II.
Subcutaneous lanadelumab for 26 weeks reduced the rate of attacks in patients with hereditary angioedema type I or II.
Tjenesten du prøver å få tilgang til er bare tilgjengelig for registrerte brukere. For å fortsette vennligst logg inn eller registrer deg for en gratis konto på Univadis